Immunoscore-IC quantifies the density of CD4 + T and CD8 + cells and the distance between their cells in the tumor microenvironment, distinguishes between patients with tumors that respond and those that do not respond to treatment with ICIs, and is considered a promising predictive marker of response to antimmunotherapy [46, 47]. The gene discussed is CD8A; the disease is neoplasm.